Gene Therapy Restores Partial Sight in Blind Patients, Nobel Laureate Reports

The research, published in the *New England Journal of Medicine*, tested a treatment for retinitis pigmentosa (RP) — a hereditary condition that progressively destroys the light-sensitive cells lining the back of the eye, eventually causing blindness. Scientists used a modified virus (an adeno-associated viral vector, or AAV) to deliver a gene directly into the eye, programming surviving cells to respond to light in a way they normally cannot.

Meanwhile, the technique draws on optogenetics — a field that uses light to control cell activity. In healthy eyes, specialised cells called photoreceptors detect light and send signals to the brain. In people with advanced RP, those cells have died. The therapy inserts a gene encoding a light-gated ion channel, essentially giving other surviving eye cells the ability to sense light and pass signals along the visual pathway.

Ten patients with advanced RP received a single injection of the viral vector directly into the vitreous — the gel-like fluid inside the eye. Deisseroth, writing as an editorial contributor to the journal, described the science behind the findings. The *NEJM* posted the editorial on its official account, noting his Nobel Prize recognition.

So why does this matter? RP affects around 1 in 3,000 to 4,000 people in the UK, according to the NHS, and there are currently very few treatment options once sight is considerably lost. A gene therapy that works through a one-time injection — rather than ongoing medication — represents a different approach to managing a condition that has long had limited options.

The research is at an early stage. A trial of ten patients cannot confirm long-term safety or how widely the treatment might work, and further studies would be needed before any therapy of this kind could reach routine clinical use.

Anyone concerned about changes to their vision should contact their GP or call NHS 111.